The incremental value of bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in a high-burden urban setting
Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB) complex, remains one of the most common and deadliest diseases worldwide, with an estimated global mortality rate of 1.6 million deaths in 2017.1, 2 Efforts to reduce mortality should focus on early diagnosis and immediate initiation of effective treatment in TB patients.2 Despite recent advances, pulmonary TB is primarily diagnosed via identification of MTB using sputum smear microscopy. However, this simple method lacks both sensitivity and specificity that are urgently needed in high-incidence settings.3, 4 Mycobacterial culture, the gold standard diagnostic technique, yields high sensitivity for detecting MTB from clinical specimens.3 Unfortunately, the lengthy procedure, due to the slow growth rate of MTB, cannot meet clinical needs for point-of-care diagnostics5 and requires an extensive laboratory infrastructure that is lacking in resource-limited settings.3
Recently, the Xpert MTB/RIF (Xpert) assay (Cepheid, Sunnyvale, CA) has been developed as an integrated system incorporating a disposable cartridge that performs both specimen processing and molecular detection.6, 7 By targeting the rpoB gene sequence of MTB, Xpert detects both the presence of MTB and its susceptibility to rifampin within 2 h.6 Several multicenter studies have demonstrated that this assay offers a level of detection sensitivity approaching that of the culture-based gold standard method.6, 8 As a consequence, Xpert is endorsed by the World Health Organization (WHO) for use in TB diagnosis, particularly for HIV-infected individuals and suspected MDR-TB cases.9 Although the application of molecular diagnostics greatly accelerates the timely acquisition of results needed for patient management decision-making, a large number of pulmonary TB patients remain undiagnosed due to a lack of microbiological evidence.1 According to a recent global TB epidemic annual report, nearly half of reported cases were diagnosed based only on patient symptoms and chest X-ray findings.1 The situation is even worse in China, where laboratory results can confirm MTB organisms in only 30% of suspected TB cases, leaving no room for doubt that the current diagnostic algorithm based on non-specific clinical manifestations results in either over- or underdiagnosis of pulmonary TB.10 Therefore, there is an urgent need to formulate a new diagnostic algorithm that adds incremental value to currently recommended TB diagnostic strategies.
Bronchoalveolar lavage fluid (BALF) is a promising alternative to the commonly used sputum specimen for detecting MTB in individuals with suspected TB, especially for patients who fail to provide sputum specimens of adequate volume or quality.11 Indeed, there is strong evidence that BALF is superior to sputum for use in bacteriological confirmation of pulmonary TB, especially for patients with smear-negative TB results.11 Thus, it would be meaningful to investigate whether the use of BALF samples collected from patients without bacteriological evidence of TB would be beneficial for clinical TB diagnostic decision-making. Indeed, little has been reported regarding this issue to date, especially with regard to strategies incorporating both Xpert and BALF. Therefore, in this study we prospectively evaluated the use of BALF specimens to assess their added incremental value to pulmonary TB diagnostic strategies used currently in a high-burden urban setting in China.
Section snippets
Ethics statement
This study was approved by the Ethics Committee of the Fifth Hospital of Suzhou. All patients enrolled in this study provided written informed consent.
Patients
A prospective study was conducted of patients with presumptive pulmonary TB who were registered in the Fifth Hospital of Suzhou between March 2018 and July 2018. All patients with symptoms suggestive of pulmonary tuberculosis were consecutively enrolled in this study. Eligible patients were at least 18 years of age and exhibited clinical symptoms
Participants
Of 440 individuals enrolled in this study, 311 (70.7%) patients were male. The median age was 48 years (range 18–89) and 19 (4.3%) cases were excluded from final analysis, including 7 due to contaminated cultures, 2 with invalid Xpert results and 10 with nontuberculous mycobacteria (NTM) infections. Of the remaining 421 cases, initial testing supported diagnoses of 245 (55.7%) as definitive TB cases due to a positive culture and/or Xpert result and 71 (16.1%) clinically diagnosed TB cases (Fig.
Discussion
In China the diagnosis of tuberculosis mainly relies on the clinical symptoms and chest radiology.17 The fact that approximately 70% of TB cases without microbiological evidence highlights the urgent need for formulation of a new diagnostic algorithm to add incremental value to current recommended strategies for TB diagnosis.1 In this study, our results demonstrated that for testing of BALF samples, Xpert significantly outperformed smear microscopy and detected TB in 97.4% of smear-negative TB
Conflict of Interest
None.
Acknowledgment
This work was supported by the Jiangsu Science and Technology Plan (BK20161230), Jiangsu Youth Medical Talents Project (QNRC2016226) and Suzhou Science and Technology Bureau Science and Technology Project for People's Livelihood (SS201879, SS201656, SS201880, SYS2018096 and SYS201778). We express our thanks to staffs in the Fifth Hospital of Suzhou for their time and effort in specimen collection.
References (26)
- et al.
Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study
Lancet
(2011) - et al.
Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence
Lancet Infect Dis
(2003) - et al.
Three year evaluation of Xpert MTB/RIF in a low prevalence tuberculosis setting: a Scottish perspective
J Infect
(2017) - et al.
Lidocaine concentrations in bronchoscopic specimens
Chest
(1988) - et al.
An outbreak of bronchoscopy-related Mycobacterium tuberculosis infections due to lack of bronchoscope leak testing
Chest
(2002) - World Health Organization. Global Tuberculosis Report 2018....
- et al.
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
Lancet Infect Dis
(2018) - et al.
Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities
Clin Microbiol Rev
(2011) - et al.
Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects
J Infect Dis
(2015) - et al.
Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China
Sci Rep
(2016)
Rapid molecular detection of tuberculosis and rifampin resistance
N Engl J Med
Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis
Eur Respir J
Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system: policy statement
Cited by (10)
Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis Based on Bronchoalveolar Lavage Fluid: A Systematic Review and Meta-analysis
2023, Infectious Microbes and DiseasesDetection of antigen Ag85B expression is useful for the diagnosis of tuberculosis, especially for those with an antituberculosis treatment history
2023, American Journal of Clinical PathologyResearch progress of Xpert MTB/RIF assay in the diagnosis of tuberculosis
2022, Chinese Journal of Clinical ResearchPrevalence and Risk Factors of Subclinical Tuberculosis in a Low-Incidence Setting in China
2022, Frontiers in MicrobiologyComparison of the diagnostic efficacy of the CapitalBio Mycobacterium real-time polymerase chain reaction detection test and Xpert MTB/RIF in smear-negative pulmonary tuberculosis
2021, European Journal of Clinical Microbiology and Infectious Diseases
- 1
These authors contributed equally to this work.